The New England Journal of Medicine

NOVEMBER 15, 2024

In patients with heart failure with preserved ejection fraction and obesity, treatment with tirzepatide led to a lower risk of death from cardiovascular causes or worsening heart-failure events than placebo.

Preserved Ejection Fraction 76

Preserved Ejection Fraction Heart Failure Obesity 76

American College of Cardiology

APRIL 6, 2024

The goal of the STEP-HFpEF DM trial was to compare the safety and efficacy of semaglutide among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM).

Preserved Ejection Fraction 69

Preserved Ejection Fraction Heart Failure Obesity Diabetes 69

American College of Cardiology

NOVEMBER 7, 2024

The goal of the EMPEROR-Preserved trial was to assess the safety and efficacy of empagliflozin in patients with symptomatic heart failure with preserved ejection fraction (HFpEF), irrespective of diabetes status.

Preserved Ejection Fraction 64

Preserved Ejection Fraction Heart Failure Diabetes Outcomes 64

American College of Cardiology

JULY 29, 2024

The goal of the CAMEO-DAPA trial was to assess whether dapagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), affects rest and exercise pulmonary capillary wedge pressure (PCWP) in patients with heart failure with preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 61

Preserved Ejection Fraction Heart Failure Exercise Pulmonary 61

Journal of Clinical Investigation - Cardiology

DECEMBER 15, 2023

Heart failure with preserved ejection fraction (HFpEF) is a widespread syndrome with limited therapeutic options and poorly understood immune pathophysiology.

Preserved Ejection Fraction 75

Preserved Ejection Fraction Heart Failure Obesity Ablation 75

American College of Cardiology

JULY 8, 2024

The goal of the PARAGON-HF trial was to evaluate the neprilysin-angiotension receptor inhibitor sacubitril/valsartan among patients with heart failure with preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 56

Preserved Ejection Fraction Heart Failure Outcomes Article 56

Medical Xpress - Cardiology

JULY 29, 2024

A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).

Preserved Ejection Fraction 111

Preserved Ejection Fraction Heart Failure Research Hospital 111

American Heart News - Heart News

JULY 24, 2024

Research Highlights: In mice with heart failure with preserved ejection fraction (HFpEF), increasing ketone supply to the heart allowed their hearts to utilize more ketones and produce more energy. Researchers hope this study may help to improve our.

Preserved Ejection Fraction 123

Preserved Ejection Fraction Heart Failure Research 123

Frontiers in Cardiovascular Medicine

JANUARY 7, 2024

Heart failure with preserved ejection fraction (HFpEF) is the largest unmet clinical need in cardiovascular medicine. Despite decades of research, the treatment option for HFpEF is still limited, indicating our ongoing incomplete understanding on the underlying molecular mechanisms.

Preserved Ejection Fraction 59

Preserved Ejection Fraction Heart Failure Biomarkers Cardiovascular Disease 59

Frontiers in Cardiovascular Medicine

NOVEMBER 17, 2024

However, its role in right ventricular (RV) function has not been evaluated.MethodsWe retrospectively analyzed the electronic medical data of 1,014 Heart Failure with Preserved Ejection Fraction (HFpEF) patients to evaluate the relationship between anemia and RV dysfunction in patients with HFpEF and whether this relationship is influenced by classical (..)

Preserved Ejection Fraction 59

Preserved Ejection Fraction Heart Failure Tricuspid Risk Factors 59

Medical Xpress - Cardiology

NOVEMBER 25, 2024

Heart failure with preserved ejection fraction (HFpEF) is underdiagnosed in patients with severe secondary tricuspid regurgitation (STR) of undefined etiology (isolated STR), according to a study published online Nov. 6 in JAMA Cardiology.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Tricuspid 40

JAMA Cardiology

APRIL 23, 2024

This systematic review and meta-analysis investigates the efficacy of catheter ablation compared with rate or rhythm control among patients with atrial fibrillation and heart failure.

Preserved Ejection Fraction 86

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 86

Science Daily - Heart Disease

AUGUST 1, 2024

A new small study has revealed the impact of obesity on muscle structure in patients having a form of heart failure called heart failure with a preserved ejection fraction (HFpEF).

Heart Failure 114

Heart Failure Preserved Ejection Fraction Obesity 114

Cardiovascular Diabetology

NOVEMBER 4, 2024

Aging is influenced by genetic determinants and comorbidities, among which diabetes increases the risk for heart failure with preserved ejection fraction. There is no therapy to prevent heart dysfunction in ag.

Preserved Ejection Fraction 52

Preserved Ejection Fraction Cardiac Function Heart Dysfunction Heart Failure 52

JAMA Cardiology

JULY 23, 2024

This randomized clinical trial investigates the effect of dapagliflozin on right ventricular performance and vascular load during exertion in heart failure with preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 110

Preserved Ejection Fraction Pulmonary Heart Failure 110

Cardiovascular Diabetology

AUGUST 30, 2024

Heart failure with preserved ejection fraction (HFpEF) is common in type 2 diabetes mellitus (T2D), leading to high morbidity and mortality. Managing HFpEF in diabetic patients is challenging with limited trea.

Preserved Ejection Fraction 59

Preserved Ejection Fraction Heart Failure Diabetes Research 59

Med Page Today

NOVEMBER 16, 2024

(MedPage Today) -- CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and accompanying heart failure with preserved ejection fraction (HFpEF), according to the SUMMIT trial. Incident.

Preserved Ejection Fraction 111

Preserved Ejection Fraction Heart Failure Obesity 111

Frontiers in Cardiovascular Medicine

MARCH 3, 2024

Introduction Heart failure with preserved ejection fraction (HFpEF) is a complex disease process influenced by metabolic disorders, systemic inflammation, myocardial fibrosis, and microvascular dysfunction.

Preserved Ejection Fraction 64

Preserved Ejection Fraction Biomarkers Heart Failure 64

JAMA Cardiology

SEPTEMBER 29, 2024

The EMBARK-HFpEF multicenter, open-label trial examines the effects of cardiac myosin inhibition with mavacamten in patients with heart failure with preserved ejection fraction with a left ventricular ejection fraction of 60% or greater.

Preserved Ejection Fraction 110

Preserved Ejection Fraction Heart Failure 110

American College of Cardiology

NOVEMBER 16, 2024

The goal of the SUMMIT trial was to compare the safety and efficacy of tirzepatide among patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

Preserved Ejection Fraction 49

Preserved Ejection Fraction Heart Failure Obesity Article 49

Science Daily - Heart Disease

JULY 24, 2024

In mice with heart failure with preserved ejection fraction (HFpEF), increasing ketone supply to the heart allowed their hearts to utilize more ketones and produce more energy.

Preserved Ejection Fraction 104

Preserved Ejection Fraction Diabetes Heart Failure 104

Science Daily - Heart Disease

SEPTEMBER 2, 2024

Finerenone reduced the composite of total first and recurrent heart failure (HF) events (hospitalizations for HF or urgent HF visits) and cardiovascular death in patients with HF and mildly reduced or preserved ejection fraction, according to an international clinical trial.

Preserved Ejection Fraction 108

Preserved Ejection Fraction Heart Failure Hospital 108

Med Page Today

OCTOBER 2, 2024

(MedPage Today) -- The novel investigational weight loss agent HU6 had mixed results specifically targeting obesity-related heart failure with preserved ejection fraction (HFpEF), based on the small HuMain-HFpEF trial. After 19 weeks on daily.

Preserved Ejection Fraction 105

Preserved Ejection Fraction Obesity Heart Failure 105

American Heart News - Heart News

NOVEMBER 16, 2024

called SUMMIT, participants with heart failure with preserved ejection fraction (HFpEF) and obesity taking tirzepatide for an average of 2 years had. Research Highlights: In an international trial of 713 adults in nine countries including the U.S.

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Obesity Research 105

JAMA Cardiology

SEPTEMBER 26, 2024

This prespecified analysis of the Finerenone Trial to Investigate the Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) randomized clinical trial investigates the long-term effects of treatment with the nonsteroidal mineralocorticoid receptor antagonist, finerenone, in patients with heart failure with mildly reduced (..)

Heart Failure 110

Heart Failure Preserved Ejection Fraction 110

The British Journal of Cardiology

JANUARY 16, 2024

Heart failure with preserved ejection fraction (HFpEF) is a common concern in the medical field due to its prevalence in an ageing western population. HFpEF is associated with significant morbidity and mortality not dissimilar to heart failure (HF) with reduced ejection fraction.

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Echocardiogram Outpatient 52

Medical Xpress - Cardiology

OCTOBER 10, 2024

Mavacamten, a drug initially developed to treat hypertrophic cardiomyopathy, has shown signs of reducing heart stress in patients with heart failure with preserved ejection fraction.

Preserved Ejection Fraction 99

Preserved Ejection Fraction Biomarkers Heart Failure Cardiomyopathy 99

European Journal of Heart Failure

DECEMBER 13, 2023

BMI, body mass index; CI, confidence interval; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide. ABSTRACT Aim Chronic obstructive pulmonary disease (COPD) is common in heart failure with a mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and is associated with worse outcomes.

Preserved Ejection Fraction 75

Preserved Ejection Fraction Heart Failure Pulmonary Quality of Life 75

JAMA Cardiology

FEBRUARY 6, 2024

This study attempts assess to the association of β-blocker treatment withdrawal on changes in the percentage of predicted peak oxygen consumption across indexed left ventricular diastolic and systolic volumes, and left ventricular ejection fraction in patients with heart failure with preserved ejection fraction and chronotropic incompetence.

Preserved Ejection Fraction 103

Preserved Ejection Fraction Heart Failure 103

Frontiers in Cardiovascular Medicine

JANUARY 28, 2024

Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) have emerged as major age-related epidemics within cardiology.

Preserved Ejection Fraction 59

Preserved Ejection Fraction Heart Failure Atrial Fibrillation Electrophysiology 59

Med Page Today

SEPTEMBER 30, 2024

(MedPage Today) -- There may be a future for cardiac myosin inhibitors in heart failure with preserved ejection fraction (HFpEF), according to the proof-of-concept EMBARK-HFpEF trial. An established cardiac myosin inhibitor for hypertrophic cardiomyopathy.

Preserved Ejection Fraction 98

Preserved Ejection Fraction Heart Failure Cardiomyopathy 98

Science Daily - Heart Disease

FEBRUARY 21, 2024

In ambulatory women ages 63-99 years, higher amounts of usual daily light and moderate intensity activities were associated with lower risk of developing heart failure with preserved ejection fraction independent of demographic and clinical factors associated with heart failure risk.

Preserved Ejection Fraction 107

Preserved Ejection Fraction Heart Failure 107

Med Page Today

APRIL 7, 2024

(MedPage Today) -- ATLANTA -- Weight loss and heart failure benefits with semaglutide (Wegovy) extended to patients with obesity-related heart failure with preserved ejection fraction (HFpEF) who have type 2 diabetes, the STEP-HFpEF DM trial showed.

Preserved Ejection Fraction 96

Preserved Ejection Fraction Diabetes Heart Failure Obesity 96

Science Daily - Heart Disease

JULY 29, 2024

A novel study co-authored by a heart failure cardiologist demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).

Preserved Ejection Fraction 92

Preserved Ejection Fraction Heart Failure 92

Medical Xpress - Cardiology

SEPTEMBER 20, 2024

For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ventricular (LV) diastolic function, according to a study published online Sept. 9 in Circulation: Heart Failure.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Circulation 40

HeartRhythm

OCTOBER 21, 2024

Clinical outcomes among patients with atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) treated with catheter ablation (CA) versus antiarrhythmic therapy (AAT) are not well-known.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

Frontiers in Cardiovascular Medicine

FEBRUARY 5, 2024

Introduction The genotype of symptomatic left ventricular noncompaction phenotype (LVNC) subjects with preserved left ventricular ejection fraction (LVEF) and its effect on clinical presentation are less well studied.

Preserved Ejection Fraction 69

Preserved Ejection Fraction Cardiomyopathy 69